{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:08:23Z","timestamp":1788736103813,"version":"build-2803163510"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103181","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:13:46Z","timestamp":1783178026000},"page":"103181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoadjuvant and adjuvant therapy in uveal melanoma: toward systemic control of a systemic disease"],"prefix":"10.1016","volume":"149","author":[{"given":"Dimitra","family":"Foteinou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Theocharopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios \u039d.","family":"Varvoglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis A.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.N.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctrv.2026.103181_bb0005","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes","volume":"127","author":"Shields","year":"2009","journal-title":"Arch. Ophthalmol."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0010","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1016\/j.jcjo.2023.12.002","article-title":"Prognostic implications of tenascin C in peripheral blood and primary tumours at the time of uveal melanoma diagnosis","volume":"59","author":"Herrspiegel","year":"2024","journal-title":"Can. J. Ophthalmol."},{"issue":"11","key":"10.1016\/j.ctrv.2026.103181_bb0015","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41416-022-01723-8","article-title":"Future perspectives of uveal melanoma blood based biomarkers","volume":"126","author":"Beasley","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res."},{"issue":"3","key":"10.1016\/j.ctrv.2026.103181_bb0025","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41433-020-1091-x","article-title":"Minimal residual disease-a novel concept in uveal melanoma","volume":"35","author":"Dunavoelgyi","year":"2021","journal-title":"Eye (Lond)"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103181_bb0030","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","article-title":"Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death","volume":"64","author":"Onken","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103181_bb0035","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0040","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41467-020-16276-8","article-title":"Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours","volume":"11","author":"Johansson","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ctrv.2026.103181_bb0045","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ophtha.2019.04.027","article-title":"Genetic analysis of uveal melanoma in 658 patients using the Cancer genome atlas classification of uveal melanoma as a, B, C, and D","volume":"126","author":"Vichitvejpaisal","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103181_bb0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103181_bb0055","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","article-title":"Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing","volume":"99","author":"Royer-Bertrand","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ctrv.2026.103181_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102499","article-title":"Mechanisms of resistance to immune checkpoint inhibitors in melanoma: what we have to overcome?","volume":"113","author":"Ziogas","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ctrv.2026.103181_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100306","article-title":"Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma","volume":"9","author":"Ferraz","year":"2025","journal-title":"J Liq Biopsy"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103181_bb0075","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2024.42.16_suppl.9510","article-title":"A phase 2 safety and efficacy study of neoadjuvant\/adjuvant darovasertib for localized ocular melanoma","volume":"42","author":"Joshua","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103181_bb0080","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (COMS): COMS report no. 15","volume":"119","author":"Group, T.C.O.M.S.","year":"2001","journal-title":"Arch. Ophthalmol."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103181_bb0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/COC.0b013e3182546a6b","article-title":"Delayed systemic recurrence of uveal melanoma","volume":"36","author":"Kolandjian","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ctrv.2026.103181_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235990","article-title":"Analysis of circulating tumour cells in early-stage uveal melanoma: evaluation of tumour marker expression to increase capture","volume":"13","author":"Beasley","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060856","article-title":"Pilot study of circulating tumor cells in early-stage and metastatic uveal melanoma","volume":"11","author":"Anand","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103181_bb0100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ajcp\/aqad029","article-title":"Multiorgan involvement of dormant uveal melanoma micrometastases in postmortem tissue from patients without coexisting macrometastases","volume":"160","author":"Gill","year":"2023","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.survophthal.2024.09.004","article-title":"Choroidal nevi and melanoma doubling times and implications for delays in treatment: a systematic review and meta-analysis","volume":"70","author":"Stalhammar","year":"2025","journal-title":"Surv. Ophthalmol."},{"issue":"8","key":"10.1016\/j.ctrv.2026.103181_bb0110","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0161-6420(00)00182-2","article-title":"Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment","volume":"107","author":"Eskelin","year":"2000","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103181_bb0115","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ophtha.2023.11.021","article-title":"Delays between uveal melanoma diagnosis and treatment increase the risk of metastatic death","volume":"131","author":"Stalhammar","year":"2024","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103181_bb0120","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jamaophthalmol.2013.2547","article-title":"Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture","volume":"131","author":"Grossniklaus","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103181_bb0125","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1096\/fj.01-0813com","article-title":"Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy","volume":"16","author":"Udagawa","year":"2002","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0130","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1167\/iovs.09-4755","article-title":"Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma","volume":"51","author":"Yang","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.ctrv.2026.103181_bb0135","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrc2256","article-title":"Models, mechanisms and clinical evidence for cancer dormancy","volume":"7","author":"Aguirre-Ghiso","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103181_bb0140","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-6420(93)31470-3","article-title":"The prognostic value of tumor blood vessel morphology in primary uveal melanoma","volume":"100","author":"Folberg","year":"1993","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103181_bb0145","first-page":"2900","article-title":"Microvessel count predicts survival in uveal melanoma","volume":"56","author":"Foss","year":"1996","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.ctrv.2026.103181_bb0150","first-page":"2471","article-title":"Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma","volume":"40","author":"Makitie","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.ctrv.2026.103181_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081061","article-title":"Molecular characteristics of uveal melanoma: insights from the Cancer genome atlas (TCGA) project","volume":"11","author":"Bakhoum","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0160","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1172\/JCI42002","article-title":"Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma","volume":"120","author":"Eyles","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18010094","article-title":"Personalizing treatment for pancreatic ductal adenocarcinoma: the emerging role of minimal residual disease in perioperative decision-making","volume":"18","author":"Theocharopoulos","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0170","doi-asserted-by":"crossref","first-page":"19406","DOI":"10.1038\/s41598-025-03915-7","article-title":"Presence of tumor DNA in aqueous humor is correlated with high risk uveal melanoma","volume":"15","author":"Barwinski","year":"2025","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.ctrv.2026.103181_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133066","article-title":"GNAQ and GNA11 genes: a comprehensive review on oncogenesis, prognosis and therapeutic opportunities in uveal melanoma","volume":"14","author":"Silva-Rodriguez","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0180","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ng.3549","article-title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma","volume":"48","author":"Moore","year":"2016","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.ctrv.2026.103181_bb0185","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.18632\/oncotarget.6614","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103181_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509968","article-title":"The role of circulating tumor DNA in melanomas of the uveal tract","volume":"15","author":"Zameer","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13046-025-03374-y","article-title":"Digital PCR-based genetic profiling from vitreous fluid as liquid biopsy for primary uveal melanoma: a proof-of-concept study","volume":"44","author":"Nell","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103181_bb0200","doi-asserted-by":"crossref","first-page":"e15037","DOI":"10.1200\/JCO.2025.43.16_suppl.e15037","article-title":"Assessing a tumor-agnostic circulating tumor DNA assay for uveal melanoma surveillance and metastatic disease monitoring","volume":"43","author":"El-Ashmawy","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.ctrv.2026.103181_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249651","article-title":"Monosomy 3 influences epithelial-mesenchymal transition gene expression in uveal melanoma patients; consequences for liquid biopsy","volume":"21","author":"Soltysova","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0210","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-01984-w","article-title":"Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma","volume":"40","author":"Bustamante","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0215","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ctrv.2026.103181_bb0220","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.ctrv.2026.103181_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071740","article-title":"Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition","volume":"13","author":"Park","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103181_bb0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/iovs.65.2.11","article-title":"Evaluation of circulating tumor DNA as a liquid biomarker in uveal melanoma","volume":"65","author":"de Bruyn","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"13","key":"10.1016\/j.ctrv.2026.103181_bb0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/iovs.63.13.17","article-title":"Detectability of plasma-derived circulating tumor DNA panel in patients undergoing primary treatment for uveal melanoma","volume":"63","author":"Francis","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103181_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.70047","article-title":"Prognostic and predictive value of ctDNA for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"38","author":"Noronha","year":"2025","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"16","key":"10.1016\/j.ctrv.2026.103181_bb0245","doi-asserted-by":"crossref","first-page":"14953","DOI":"10.1007\/s00432-023-05271-3","article-title":"Detection of metastases using circulating tumour DNA in uveal melanoma","volume":"149","author":"Beasley","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103181_bb0250","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-25-2274","article-title":"Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma","volume":"32","author":"Ramelyte","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.ctrv.2026.103181_bb0255","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with Tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctrv.2026.103181_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70286","article-title":"Minimal residual disease in solid tumors: clinical applications and future directions","volume":"132","author":"Abdo","year":"2026","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103181_bb0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","article-title":"Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort","volume":"35","author":"Henriksen","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0270","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/pcmr.12708","article-title":"Oncogenic signaling in uveal melanoma","volume":"31","author":"Park","year":"2018","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"4","key":"10.1016\/j.ctrv.2026.103181_bb0275","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41388-020-01569-5","article-title":"Functional characterization of uveal melanoma oncogenes","volume":"40","author":"Ma","year":"2021","journal-title":"Oncogene"},{"issue":"39","key":"10.1016\/j.ctrv.2026.103181_bb0280","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1038\/onc.2013.418","article-title":"Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations","volume":"33","author":"Chen","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029622","article-title":"The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103181_bb0290","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1158\/1535-7163.MCT-12-0121","article-title":"Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC\/Erk1\/2 and PKC\/NF-kappaB pathways","volume":"11","author":"Wu","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"39","key":"10.1016\/j.ctrv.2026.103181_bb0295","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1038\/onc.2013.555","article-title":"Combined PKC and MEK inhibition for treating metastatic uveal melanoma","volume":"33","author":"Sagoo","year":"2014","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103181_bb0300","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1021\/acs.jmedchem.3c02002","article-title":"Discovery of Darovasertib (NVP-LXS196), a Pan-PKC inhibitor for the treatment of metastatic uveal melanoma","volume":"67","author":"Visser","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0305","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41416-022-02133-6","article-title":"A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma","volume":"128","author":"Piperno-Neumann","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctrv.2026.103181_bb0310","author":"IDEAYA Biosciences"},{"key":"10.1016\/j.ctrv.2026.103181_bb0315","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: a first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103181_bb0320","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with Tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ctrv.2026.103181_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102718","article-title":"Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment","volume":"15","author":"Ziogas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103181_bb0330","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103181_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0340","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus Ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0345","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and Ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7934","key":"10.1016\/j.ctrv.2026.103181_bb0350","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103181_bb0355","doi-asserted-by":"crossref","first-page":"9509","DOI":"10.1200\/JCO.2024.42.16_suppl.9509","article-title":"Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309)","volume":"42","author":"Rapisuwon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2026.103181_bb0360","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with Dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctrv.2026.103181_bb0365","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.cmr.0000205017.38859.07","article-title":"A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma","volume":"16","author":"O\u2019Neill","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ctrv.2026.103181_bb0370","series-title":"Etude randomis\u00e9e de chimioth\u00e9rapie adjuvante par le D\u00e9tic\u00e8ne dans le m\u00e9lanome choro\u00efdien","author":"Desjardins","year":"1998"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103181_bb0375","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/bjophthalmol-2019-314461","article-title":"A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes","volume":"104","author":"Binkley","year":"2020","journal-title":"Br. J. Ophthalmol."},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2026.103181_bb0380","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2017.35.15_suppl.9502","article-title":"A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ)","volume":"35","author":"Piperno-Neumann","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctrv.2026.103181_bb0385","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.ctrv.2026.103181_bb0390","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/modpathol.2011.57","article-title":"KIT mutations in ocular melanoma: frequency and anatomic distribution","volume":"24","author":"Wallander","year":"2011","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103181_bb0395","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1167\/iovs.09-4739","article-title":"Regulation of VEGF-A in uveal melanoma","volume":"51","author":"el Filali","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2026.103181_bb0400","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1200\/jco.2010.28.15_suppl.8577","article-title":"Final results of a pilot study using sunitinib malate in patients with stage IV uveal melanoma","volume":"28","author":"Tijani","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctrv.2026.103181_bb0405","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ophtha.2017.08.017","article-title":"Adjuvant Sunitinib in high-risk patients with uveal melanoma: comparison with institutional controls","volume":"125","author":"Valsecchi","year":"2018","journal-title":"Ophthalmology"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103181_bb0410","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1200\/JCO.2022.40.16_suppl.9586","article-title":"Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: the final analysis of cohort 1","volume":"40","author":"Seedor","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103181_bb0415","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/CMR.0000000000000118","article-title":"C-MET expression in primary and liver metastases in uveal melanoma","volume":"24","author":"Gardner","year":"2014","journal-title":"Melanoma Res."},{"issue":"12","key":"10.1016\/j.ctrv.2026.103181_bb0420","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1167\/iovs.05-0322","article-title":"Receptors for the liver synthesized growth factors IGF-1 and HGF\/SF in uveal melanoma: intercorrelation and prognostic implications","volume":"46","author":"Economou","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.ctrv.2026.103181_bb0425","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","article-title":"Crizotinib, a c-met inhibitor, prevents metastasis in a metastatic uveal melanoma model","volume":"12","author":"Surriga","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctrv.2026.103181_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.976837","article-title":"Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy","volume":"12","author":"Khan","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0435","doi-asserted-by":"crossref","first-page":"2571773","DOI":"10.1080\/2162402X.2025.2571773","article-title":"Dendritic cells: the central partner for cancer immunity","volume":"14","author":"Laoubi","year":"2025","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103181_bb0440","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.ophtha.2016.06.027","article-title":"Adjuvant dendritic cell vaccination in high-risk uveal melanoma","volume":"123","author":"Bol","year":"2016","journal-title":"Ophthalmology"},{"issue":"37","key":"10.1016\/j.ctrv.2026.103181_bb0445","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103181_bb0450","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1158\/1078-0432.CCR-09-0547","article-title":"JNJ-26481585, a novel \u201csecond-generation\u201d oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity","volume":"15","author":"Arts","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ctrv.2026.103181_bb0455","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1541-7786.MCR-20-0434","article-title":"Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity Spectrum for BAP1-mutant uveal melanoma","volume":"19","author":"Kuznetsoff","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"13","key":"10.1016\/j.ctrv.2026.103181_bb0460","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.7150\/ijbs.27661","article-title":"The HDAC inhibitor Quisinostat (JNJ-26481585) Supresses hepatocellular carcinoma alone and synergistically in combination with Sorafenib by G0\/G1 phase arrest and apoptosis induction","volume":"14","author":"He","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.ctrv.2026.103181_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020152","article-title":"Adjuvant Ipilimumab in High-Risk Uveal Melanoma","volume":"11","author":"Fountain","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0470","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12885-022-09464-w","article-title":"The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature","volume":"22","author":"Hagstrom","year":"2022","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103181_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26092506","article-title":"Melatonin in Cancer treatment: current knowledge and future opportunities","volume":"26","author":"Talib","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0480","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1038\/s41598-025-93486-4","article-title":"Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma","volume":"15","author":"Guo","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103181_bb0485","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00008390-199702000-00005","article-title":"Melatonin inhibits growth of cultured human uveal melanoma cells","volume":"7","author":"Hu","year":"1997","journal-title":"Melanoma Res."},{"issue":"3","key":"10.1016\/j.ctrv.2026.103181_bb0490","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-079X.2001.280306.x","article-title":"Melatonin receptors in human uveal melanocytes and melanoma cells","volume":"28","author":"Roberts","year":"2000","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.ctrv.2026.103181_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125160","article-title":"Combination of Apigenin and melatonin with nanostructured lipid carriers as anti-inflammatory ocular treatment","volume":"670","author":"Bonilla-Vidal","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ctrv.2026.103181_bb0500","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1600-079X.2005.00258.x","article-title":"Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis","volume":"39","author":"Mills","year":"2005","journal-title":"J. Pineal Res."},{"issue":"7","key":"10.1016\/j.ctrv.2026.103181_bb0505","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","article-title":"Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial","volume":"31","author":"Wermke","year":"2025","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103181_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051215","article-title":"TCR-directed therapy in the treatment of metastatic uveal melanoma","volume":"14","author":"Strobel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103181_bb0515","doi-asserted-by":"crossref","first-page":"1232787","DOI":"10.3389\/fphar.2023.1232787","article-title":"Darovasertib, a novel treatment for metastatic uveal melanoma","volume":"14","author":"Cao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctrv.2026.103181_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1619150","article-title":"Advances in immunotherapy for uveal melanoma: enhancing efficacy and overcoming resistance","volume":"13","author":"Song","year":"2025","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:28:49Z","timestamp":1788733729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":104,"alternative-id":["S0305737226000952"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103181","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant and adjuvant therapy in uveal melanoma: toward systemic control of a systemic disease","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103181"}}